Patents by Inventor Sang-Ryeol Shim
Sang-Ryeol Shim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230265196Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed cell Death 1 receptor (PD-1) and a vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist, and the use of the combination therapies for the treatment of a cancer. In an embodiment, the cancer is a glioblastoma, a breast cancer, a triple negative breast cancer, a metastatic breast cancer, or a metastatic triple negative breast cancer.Type: ApplicationFiled: September 2, 2021Publication date: August 24, 2023Inventors: Seon Young Lee, Weon Sup Lee, Jin-San Yoo, Sang Ryeol Shim
-
Patent number: 10597457Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.Type: GrantFiled: November 25, 2014Date of Patent: March 24, 2020Assignee: PHARMABCINE INC.Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
-
Patent number: 10155817Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.Type: GrantFiled: March 14, 2018Date of Patent: December 18, 2018Assignee: PharmAbcine Inc.Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
-
Patent number: 10125194Abstract: The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.Type: GrantFiled: July 22, 2009Date of Patent: November 13, 2018Assignee: PHARMABCINE INC.Inventors: Jin San Yoo, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim
-
Patent number: 10106622Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.Type: GrantFiled: July 28, 2015Date of Patent: October 23, 2018Assignee: PHARMABCINE INC.Inventors: Jinsang Yoo, Ju Ryoung Nam, Jin San Yoo, Sung-Woo Kim, Weon Sup Lee, Sang Ryeol Shim, Sang Soon Byun, Miju Park, Hyuk Joon Lee, Do Yun Kim, Yeon Ju Kim, Mi Ae Jeon, Jinhee Choi, Youngae Lee, Kyoung Hee Nahm, Boyoung Jeong, Seon Young Lee, Jong Geun Jeong, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh, Eun Hee Lee, Ji Hye Jeong
-
Publication number: 20180208660Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.Type: ApplicationFiled: March 14, 2018Publication date: July 26, 2018Applicant: PharmAbcine Inc.Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
-
Patent number: 9963512Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.Type: GrantFiled: November 20, 2013Date of Patent: May 8, 2018Assignee: PharmAbcine Inc.Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
-
Publication number: 20170327585Abstract: The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.Type: ApplicationFiled: November 25, 2014Publication date: November 16, 2017Inventors: Jae Bong Yoon, Jinsang Yoo, Jin-San Yoo, Weon Sup Lee, Sung-Woo Kim, Sang Ryeol Shim, Sang Soon Byun, Youngae Lee, Hyuk Joon Lee, Do-yun Kim, Jinhee Choi
-
Publication number: 20170233492Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.Type: ApplicationFiled: July 28, 2015Publication date: August 17, 2017Inventors: Jinsang Yoo, Ju Ryoung Nam, Jin San Yoo, Sung-Woo Kim, Weon Sup Lee, Sang Ryeol Shim, Sang Soon Byun, Miju Park, Hyuk Joon Lee, Do Yun Kim, Yeon Ju Kim, Mi Ae Jeon, Jinhee Choi, Youngae Lee, Kyoung Hee Nahm, Boyoung Jeong, Seon Young Lee, Jong Geun Jeong, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh, Eun Hee Lee, Ji Hye Jeong
-
Patent number: 9249219Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Patent number: 9249220Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20150315277Abstract: The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.Type: ApplicationFiled: November 20, 2013Publication date: November 5, 2015Applicant: PharmAbcine Inc.Inventors: Joong Kyu Kim, Jin San Yoo, Sang Hoon Lee, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim, Jin Sang Yoo, Young Ae Lee, Mi Ju Park, Sang Soon Byun, Hyuk Joon Lee, Do Yun Kim, Yeun Ju Kim, Jin Hee Choi, Kyung Hee Nahm, Ju Ryung Nam, Jong Geun Jeong, Bo Young Jeong, Eun Jin Lee, Seon Young Lee, In Sook Park, Jin Sook Lee, Jae Bong Yoon, Nam Ye Kim, Seon Hwan Oh
-
Patent number: 9150650Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: June 26, 2007Date of Patent: October 6, 2015Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Se-mi Kim, Sang-Seok Koh
-
Publication number: 20140288274Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 25, 2014Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20140275488Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: PHARMABCINE INC.Inventors: Jin-San YOO, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20120065380Abstract: The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.Type: ApplicationFiled: July 22, 2009Publication date: March 15, 2012Applicant: Pharmabcine Inc.Inventors: Jin San Yoo, Weon Sup Lee, Sung Woo Kim, Sang Ryeol Shim
-
Publication number: 20110065176Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: June 26, 2007Publication date: March 17, 2011Applicant: Korea Research Institute of BioScience and BioTechnologyInventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong- Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae -Won Jeon, Dong- Sup Lee, Young-Woo Park, Geun - Bae Rha, Hyun-Sook Jang, Hyeon- Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh